EC 18 - Enzychem Lifesciences

Drug Profile

EC 18 - Enzychem Lifesciences

Alternative Names: EC18

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzychem Lifesciences Corporation
  • Class Antineoplastics; Chemoprotectants
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Macrophage stimulants; Neutrophil stimulants; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia; Stomatitis
  • Preclinical Sepsis

Most Recent Events

  • 19 Jan 2018 EC 18 - Enzychem Lifesciences receives Orphan Drug status for Acute radiation syndrome in USA
  • 01 Jan 2018 Phase-II clinical trials in Stomatitis in USA (PO) (NCT03200340)
  • 02 Aug 2017 The US FDA approves IND application for EC-18 in Mucositis (Chemontherapy-induced)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top